-
Standardizing Healthtech Evidence to Meet NICE Expectations
Sep 9, 2025, 16:22 PM -
Clinical Profile of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated With Complement Inhibitors: Results From a Real-World Study
Sep 9, 2025, 16:22 PM -
From Policy to Practice: Are Larger Member States Leading the Way for Joint Clinical Assessments?
Sep 9, 2025, 16:22 PM -
Predicting SMC Appraisal Outcomes Using Machine Learning: A Model to Support Early Market Access Strategy
Sep 9, 2025, 16:22 PM -
Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment
Sep 9, 2025, 16:22 PM -
Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)
Sep 9, 2025, 16:22 PM -
Implementation and Outcomes of Managed Entry Agreements Across the Nordic Region
Sep 9, 2025, 16:22 PM -
A Comparison of Treatment Costs for CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative HR+/HER2-: Early Breast Cancer (EBC) in Sweden
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal
Sep 9, 2025, 16:22 PM -
Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis
Sep 9, 2025, 16:22 PM -
Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries
Sep 9, 2025, 16:22 PM -
A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States
Sep 9, 2025, 16:22 PM -
COPD-Asthma Overlap in Brazilian Private Healthcare: Clinical Profiles and Outcomes from a Real-World Analysis
Sep 9, 2025, 16:22 PM -
Comparing the Time to Reimbursement of the Orphan Drug Evrysdi in Turkiye vs. Euro-5 Markets
Sep 9, 2025, 16:22 PM -
Societal Impact Analysis of Introducing Elexacaftor Tezacaftor Ivacaftor (ELX TEZ IVA) in the Management of People With Cystic Fibrosis in Germany: A Paid and Unpaid Work Productivity Approach
Sep 9, 2025, 16:22 PM -
Bridging the Regulatory-Payer Evidence Gap: A Case Study With Six Minute Walk Distance and Mortality
Sep 9, 2025, 16:22 PM -
Proportion of the Expenses of Over-the-Counter Equivalent Drugs Among Total Healthcare an Analysis Using the Wellness-Star☆ Database
Sep 9, 2025, 16:22 PM -
Exploring the Broader Value of Adult Respiratory Vaccination Programs in Greece: A Public Health Perspective
Sep 9, 2025, 16:22 PM -
Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States
Sep 9, 2025, 16:22 PM -
Psychometric Validation Of The North Star Assessment For Limb-Girdle Type Muscular Dystrophies (NSAD) In Limb-Girdle Muscular Dystrophy Sarcoglycanopathies (LGMD 2C/2D/2E) Using Baseline JOURNEY Data...
Sep 9, 2025, 16:22 PM
